載入...
The Clinical Development Program of Lixisenatide: A Once-Daily Glucagon-Like Peptide-1 Receptor Agonist
Lixisenatide (AVE0010) is a once-daily glucagon-like peptide-1 (GLP-1) receptor agonist used in the treatment of type 2 diabetes. Phase II dose-finding and pharmacodynamic studies identified the 20 µg once-daily dose as having the optimum combination of efficacy, convenience and tolerability. Lixise...
Na minha lista:
| 發表在: | Diabetes Ther |
|---|---|
| 主要作者: | |
| 格式: | Artigo |
| 語言: | Inglês |
| 出版: |
Springer Healthcare
2014
|
| 主題: | |
| 在線閱讀: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4269639/ https://ncbi.nlm.nih.gov/pubmed/25027491 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s13300-014-0073-z |
| 標簽: |
添加標簽
沒有標簽, 成為第一個標記此記錄!
|